On this page Agenda Applications for consideration at this meeting 1354.1 Intravascular ultrasound guided coronary stent insertion 1634 Comprehensive genomic profiling of non-small cell lung cancer tumour tissue specimens using next generation sequencing assays 1643 Two testing options for determining eligibility for access to Pharmaceutical Benefits Schedule-subsidised aducanumab in patients with early stage Alzheimer Disease 1646 Whole genome sequencing of antimicrobial-resistant pathogens 1656 Vertebral body tethering for adolescent idiopathic scoliosis 1658 Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer for access to PBS olaparib 1659 Catheter-based renal denervation for uncontrolled elevated systolic blood pressure 1660 Diagnostic testing for mesenchymal-epithelial transition Exon 14 skipping alterations in non-small cell lung cancer, to determine Pharmaceutical Benefits Scheme eligibility for tepotinib treatment 1661 Implantation of minimally invasive interspinous decompression spacers for moderate degenerative lumbar spinal stenosis Related information Committee: PICO Advisory Subcommittee (PASC)